Bicycle Therapeutics (BCYC) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bicycle Therapeutics is the larger company by market cap ($266.7 million vs $248.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | VCRE |
|---|---|---|
| Share price | $3.81 | $8.82 |
| Market cap | $266.67M | $248.41M |
| 1-day change | +2.14% | +1.85% |
| YTD return | -46.19% | — |
| 1-year return | -53.87% | — |
| 5-year return | -93.57% | — |
| EPS (TTM) | $-2.73 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.16 | $17.80 |
| 52-week low | $3.33 | $7.88 |
| Distance from 52-week high | -58.40% | -50.45% |
| Analyst consensus | none | none |
| Avg. price target upside | +149.34% | +275.96% |
| Average volume | 391.03K | 16.24K |
| Shares outstanding | 50.55M | 28.16M |
| Employees | 288 | 46 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Bicycle Therapeutics in Healthcare and Vicore Pharma AB in Health Care.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Healthcare · Biotechnology · 288 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
BCYC vs VCRE FAQ
Which is bigger, Bicycle Therapeutics or Vicore Pharma AB?
Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $266.67M compared with $248.41M for Vicore Pharma AB (VCRE).
Are Bicycle Therapeutics and Vicore Pharma AB in the same industry?
No. Bicycle Therapeutics is in the Healthcare sector, while Vicore Pharma AB is in Health Care.